VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induc...

Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing nov...

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(...

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.

Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences (NASDAQ:VTYX) with a Buy and lowers the price target from...

Wells Fargo analyst Derek Archila upgrades Ventyx Biosciences (NASDAQ:VTYX) from Equal-Weight to Overweight and raises the p...

Oppenheimer analyst Jeff Jones upgrades Ventyx Biosciences (NASDAQ:VTYX) from Perform to Outperform and announces $12 price ...

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning higher on Monday. The Dow traded up 0.08%...